Elekta, a global leader in precision radiation therapy, is preparing to launch Elekta Evo, an advanced AI-enabled CT-Linac designed to deliver Adaptive Radiation Therapy (ART) for more precise and personalized cancer treatment. With India reporting more than 1.4 million cancer cases annually—many diagnosed at late stages—the new system aims to help clinicians deliver real-time, highly targeted therapy that can improve treatment outcomes and enhance patients’ quality of life.
ART tailors each radiation session to real-time changes in a tumour’s shape, size, and position, ensuring radiation is delivered with maximum accuracy. This approach increases treatment effectiveness, reduces side effects, and gives clinicians greater control throughout therapy. The need for ART is especially significant in India, where head and neck cancers make up nearly 30% of all cancer cases, and breast, cervical, and prostate cancers remain highly prevalent.
Elekta, headquartered in Stockholm and operating in more than 40 countries with 4,500 employees, continues to focus on delivering precision-driven, sustainable, and outcome-focused cancer care through advanced technology and global partnerships.
Click here to read the original news story.